(NASDAQ: SLDB) Solid Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.66%.
Solid Biosciences's earnings in 2026 is -$174,325,000.On average, 16 Wall Street analysts forecast SLDB's earnings for 2026 to be -$166,261,642, with the lowest SLDB earnings forecast at -$208,560,068, and the highest SLDB earnings forecast at -$142,569,014. On average, 14 Wall Street analysts forecast SLDB's earnings for 2027 to be -$169,075,634, with the lowest SLDB earnings forecast at -$201,239,755, and the highest SLDB earnings forecast at -$116,741,294.
In 2028, SLDB is forecast to generate -$88,857,196 in earnings, with the lowest earnings forecast at -$141,742,527 and the highest earnings forecast at -$12,397,306.